Home/Filings/4/0001140361-14-027289
4//SEC Filing

Echo Therapeutics, Inc. 4

Accession 0001140361-14-027289

CIK 0001031927operating

Filed

Jun 30, 8:00 PM ET

Accepted

Jul 1, 6:24 PM ET

Size

19.3 KB

Accession

0001140361-14-027289

Insider Transaction Report

Form 4
Period: 2014-06-27
LANDESMAN URI
10% Owner
Transactions
  • Purchase

    Common Stock

    2014-06-27$2.20/sh+10,656$23,443623,369 total(indirect: By Platinum Partners Liquid Opportunity Master Fund L.P.)
  • Purchase

    Common Stock

    2014-06-30$2.20/sh+55,083$121,183678,452 total(indirect: By Platinum Partners Liquid Opportunity Master Fund L.P.)
Holdings
  • Common Stock

    (indirect: By Platinum Partners Value Arbitrage Fund L.P.)
    1,605,424
Transactions
  • Purchase

    Common Stock

    2014-06-30$2.20/sh+55,083$121,183678,452 total(indirect: By Platinum Partners Liquid Opportunity Master Fund L.P.)
  • Purchase

    Common Stock

    2014-06-27$2.20/sh+10,656$23,443623,369 total(indirect: By Platinum Partners Liquid Opportunity Master Fund L.P.)
Holdings
  • Common Stock

    (indirect: By Platinum Partners Value Arbitrage Fund L.P.)
    1,605,424
Transactions
  • Purchase

    Common Stock

    2014-06-27$2.20/sh+10,656$23,443623,369 total(indirect: By Platinum Partners Liquid Opportunity Master Fund L.P.)
  • Purchase

    Common Stock

    2014-06-30$2.20/sh+55,083$121,183678,452 total(indirect: By Platinum Partners Liquid Opportunity Master Fund L.P.)
Holdings
  • Common Stock

    (indirect: By Platinum Partners Value Arbitrage Fund L.P.)
    1,605,424
Transactions
  • Purchase

    Common Stock

    2014-06-27$2.20/sh+10,656$23,443623,369 total(indirect: By Platinum Partners Liquid Opportunity Master Fund L.P.)
  • Purchase

    Common Stock

    2014-06-30$2.20/sh+55,083$121,183678,452 total(indirect: By Platinum Partners Liquid Opportunity Master Fund L.P.)
Holdings
  • Common Stock

    (indirect: By Platinum Partners Value Arbitrage Fund L.P.)
    1,605,424
Transactions
  • Purchase

    Common Stock

    2014-06-30$2.20/sh+55,083$121,183678,452 total(indirect: By Platinum Partners Liquid Opportunity Master Fund L.P.)
  • Purchase

    Common Stock

    2014-06-27$2.20/sh+10,656$23,443623,369 total(indirect: By Platinum Partners Liquid Opportunity Master Fund L.P.)
Holdings
  • Common Stock

    (indirect: By Platinum Partners Value Arbitrage Fund L.P.)
    1,605,424
Transactions
  • Purchase

    Common Stock

    2014-06-30$2.20/sh+55,083$121,183678,452 total(indirect: By Platinum Partners Liquid Opportunity Master Fund L.P.)
  • Purchase

    Common Stock

    2014-06-27$2.20/sh+10,656$23,443623,369 total(indirect: By Platinum Partners Liquid Opportunity Master Fund L.P.)
Holdings
  • Common Stock

    (indirect: By Platinum Partners Value Arbitrage Fund L.P.)
    1,605,424
Transactions
  • Purchase

    Common Stock

    2014-06-30$2.20/sh+55,083$121,183678,452 total(indirect: By Platinum Partners Liquid Opportunity Master Fund L.P.)
  • Purchase

    Common Stock

    2014-06-27$2.20/sh+10,656$23,443623,369 total(indirect: By Platinum Partners Liquid Opportunity Master Fund L.P.)
Holdings
  • Common Stock

    (indirect: By Platinum Partners Value Arbitrage Fund L.P.)
    1,605,424
Footnotes (3)
  • [F1]This Form 4 is filed jointly by Platinum Partners Value Arbitrage Fund L.P. ("PPVA"), Platinum Partners Liquid Opportunity Master Fund L.P. ("PPLO"), Platinum-Montaur Life Sciences, LLC ("Platinum-Montaur"), Platinum Management (NY) LLC ("Platinum Management"), Platinum Liquid Opportunity Management (NY) LLC ("Platinum Liquid Management"), Mark Nordlicht and Uri Landesman (collectively, the "Reporting Persons"). Each of the Reporting Persons may be deemed to be a member of a Section 13(d) group that collectively owns more than 10% of the Issuer's outstanding shares of Common Stock. Each of the Reporting Persons disclaims beneficial ownership of the shares of Common Stock reported herein except to the extent of his or its pecuniary interest therein.
  • [F2]Securities owned directly by PPLO. Each of Platinum Liquid Management, as the Investment Manager of PPLO, and Mark Nordlicht and Uri Landesman, as the Chief Investment Officer and President, respectively, of Platinum Liquid Management, may be deemed to beneficially own the securities owned directly by PPLO.
  • [F3]Securities owned directly by PPVA. Each of Platinum Management, as the Investment Manager of PPVA, and Mark Nordlicht and Uri Landesman, as the Chief Investment Officer and President, respectively, of Platinum Management, may be deemed to beneficially own the securities owned directly by PPVA.

Documents

1 file

Issuer

Echo Therapeutics, Inc.

CIK 0001031927

Entity typeoperating
IncorporatedDE

Related Parties

1
  • filerCIK 0001031927

Filing Metadata

Form type
4
Filed
Jun 30, 8:00 PM ET
Accepted
Jul 1, 6:24 PM ET
Size
19.3 KB